论文部分内容阅读
目的:探讨在131I治疗甲亢之前服用甲巯咪唑(MMI)对131I疗效的影响。方法:甲亢患者201例随机分为两组,对照组115例,未接受任何抗甲状腺药物治疗或药物治疗后但已停药3~4周,直接接受131I治疗;观察组86例接受甲巯咪唑治疗1月以上,再接受131I治疗1月后逐渐停药。治疗后6月,根据患者FT3、FT4、TSH水平评价疗效。结果:在治疗后6个月,对照组和观察组患者中分别有21例(18.3%)及14例(16.3%)仍处于甲亢,有12(10.4%)及8例(9.3%)发生甲低,有82例(71.3%)及64例(74.4%)患者甲状腺功能维持正常。总的治愈率分别为81.7%(94例)及83.7%(72例)。两组疗效比较无统计学性差异(P>0.05)。结论:在适量增加131I治疗剂量的条件下,治疗前应用甲巯咪唑治疗不会影响131I的疗效。
Objective: To investigate the effect of 131I treatment with methimazole (MMI) before 131I treatment of hyperthyroidism. Methods: 201 hyperthyroidism patients were randomly divided into two groups, control group of 115 patients without any anti-thyroid drug treatment or drug treatment but has been discontinued for 3 to 4 weeks, 131I treatment directly; the observation group of 86 patients receiving methimazole Treatment of more than 1 month, and then accept 131I treatment after 1 month gradually withdrawal. After 6 months of treatment, the efficacy was evaluated according to the level of FT3, FT4 and TSH in patients. RESULTS: Six months after treatment, 21 (18.3%) and 14 (16.3%) patients in the control group and the observation group were still hyperthyroidism, with 12 (10.4%) and 8 (9.3% In 82 cases (71.3%) and 64 cases (74.4%), thyroid function remained normal. The overall cure rates were 81.7% (94 cases) and 83.7% (72 cases). There was no significant difference between the two groups (P> 0.05). CONCLUSIONS: The use of methimazole prior to treatment did not affect the efficacy of 131I with a modest increase in the 131I dose.